Immuron (ASX:IMC) has closed the financial year 2025 with record sales and significant progress across its clinical programs, positioning the company for another pivotal year ahead. …
Latest Video
New Stories
-
Argent BioPharma advances epilepsy strategy with CannPal acquisition
April 13, 2026 - -
Telix signs new cancer development deal with Regeneron
April 13, 2026 - - Australian Biotech -
Australia risks falling further behind on access to new medicines without action, industry warns
April 13, 2026 - - Latest News -
HTA Review timeline set to extend well into the second half of 2027
April 13, 2026 - - Latest News -
The endpoint now coming into view was, in truth, always the most likely one
April 12, 2026 - - Latest News -
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News